立方制药：拟3400万元转让美沙拉秦肠溶片药品上市许可持有人及相关权益

Core Viewpoint - The company, Lifan Pharmaceutical (003020.SZ), announced the signing of a contract with Kew Flower Pharmaceutical Group Jiamusi Luling Pharmaceutical Co., Ltd. for the transfer of the marketing authorization holder (MAH) rights of Mesalazine Enteric-Coated Tablets for 34 million yuan [1] Group 1 - The transaction does not constitute a related party transaction or a major asset restructuring [1] - The transfer is subject to approval from the National Medical Products Administration [1] - After the transfer is completed, the company will continue to provide contract manufacturing services for the product to the buyer for the next two years [1]